Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05526222
PHASE3

A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

View on ClinicalTrials.gov

Summary

A multicenter, randomized, double-blind, placebo-controlled phase III clinical study of jaktinib hydrochloride tablets in the treatment of adult patients with moderate and severe atopic dermatitis

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of Jaktinib Hydrochloride Tablets in the Treatment of Adult Patients With Moderate and Severe Atopic Dermatitis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

443

Start Date

2022-07-14

Completion Date

2026-09

Last Updated

2026-01-05

Healthy Volunteers

No

Interventions

DRUG

Jaktinib Hydrochloride Tablet

Orally administered, twice a day

Locations (1)

139 People's Middle Road

Changsha, Hunan, China